tuberculosis
Conditions
Interventions
Experimental group:4-month short-course chemotherapy (2HRZE/2HR) Bovine tuberculosis immunotherapy
Control group:Standard 6-month chemotherapy (2HRZE/4HR)
Sponsors
Mianzhu People’s Hospital
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 15–65 years; 2. Newly diagnosed pulmonary tuberculosis, sputum smear negative, positive for Mycobacterium tuberculosis complex by Xpert MTB/RIF test, and sensitive to rifampicin; 3. Never received anti-tuberculosis treatment; 4. Willing and able to comply with study visits, treatment regimen, laboratory tests, and 18-month follow-up; 5. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Diagnosed or suspected rifampicin-resistant tuberculosis or non-tuberculous mycobacterial disease; 2. Contraindications to Micard or any anti-tuberculosis FDC drugs (H, R, Z, E); 3. Severe pulmonary tuberculosis requiring a course longer than 6 months (such as miliary tuberculosis); 4. Use of other immunosuppressants within the past 3 months; 5. Presence of severe communication disorders or mental illness; 6. Women who are pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cure rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-year recurrence rate;CD4-positive T lymphocyte ;Immunoglobulin G; | — |
Countries
China
Contacts
Public ContactWenqiu Deng
Mianzhu People’s Hospital
Outcome results
None listed